Elite intros generic methotrexate sodium
Elite, a specialty pharmaceutical company developing niche generic products, has launched generic methotrexate sodium 2.5 mg tablets.
Methotrexate sodium tablets are a dihydrofolate reductase inhibitor indicated for the treatment of adults with acute lymphoblastic leukemia as part of a combination chemotherapy maintenance regimen, mycosis fungoides, relapsed or refractory non-Hodgkin's lymphoma as part of a metronomic combination regimen, rheumatoid arthritis and severe psoriasis; and for the treatment of pediatric patients with polyarticular juvenile idiopathic arthritis and acute lymphoblastic leukemia as part of a combination chemotherapy maintenance regimen.
[FDA approves Elite’s generic Methotrexate]
This product is marketed and sold under the Elite Laboratories label.
Methotrexate sodium 2.5 mg tablets had a market value of approximately $63 million for the 12 months ended May 2024, per IQVIA.
[Read more: Elite Pharmaceuticals files ANDA for generic opiate analgesic product]